India's Marksans Pharma up on UK regulator nod for unit's seizure drug

Marksans Pharma

28/05/2024 07:53

** Shares of Marksans Pharma  MARK.NS  rose as much as 2.8%;
last up 0.9% to 166.2 rupees
    ** Co's unit got marketing authorisation from UK drug
regulator for Levetiracetam Relonchem 100 mg/mL oral solution
used in seizure treatment
    ** Stock on track for second straight monthly climb, up 1.5%
in May after falling for four straight months through March
    ** Stock up ~3% YTD vs ~13% climb in Nifty Pharma index
 .NIPHARM , of which MARK is not a member

 (Reporting by Varun Vyas in Bengaluru)
 ((varunvyas.hebbalalu@thomsonreuters.com))